<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="1" ids="3098">Bile acids</z:chebi> may play a role in the pathogenesis of <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> (BE) </plain></SENT>
<SENT sid="1" pm="."><plain>Bile composition can be influenced by oral administration of <z:chebi fb="1" ids="9907">ursodeoxycholic acid</z:chebi> (UDCA) </plain></SENT>
<SENT sid="2" pm="."><plain>We prospectively investigated the effect of <z:chebi fb="0" ids="49200">proton pump inhibitors</z:chebi> (<z:chebi fb="4" ids="53266">PPI</z:chebi>) supplemented with UDCA in vivo in patients with BE </plain></SENT>
<SENT sid="3" pm="."><plain>Patients with no or low-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> who were clinically asymptomatic on <z:chebi fb="4" ids="53266">PPI</z:chebi> were eligible for the study </plain></SENT>
<SENT sid="4" pm="."><plain>In order to exclude the effects of <z:e sem="disease" ids="C0017168" disease_type="Disease or Syndrome" abbrv="GERD">acid reflux</z:e>, <z:hpo ids='HP_0000001'>all</z:hpo> patients were initially treated with 40 mg <z:chebi fb="0" ids="50275">esomeprazole</z:chebi> (ESO) twice daily for 6 months and continued on this dose till the end of the study (t = 12 months) </plain></SENT>
<SENT sid="5" pm="."><plain>During a period of 6 months (t = 6 month - t = 12 month) patients were treated with oral UDCA (600 mg twice daily) </plain></SENT>
<SENT sid="6" pm="."><plain>Patients underwent endoscopy at t = 0 months, t = 6 months and t = 12 months with multiple biopsies of the distal and proximal BE segment, <z:mpath ids='MPATH_458'>normal</z:mpath> squamous and gastric cardia </plain></SENT>
<SENT sid="7" pm="."><plain>In addition, pH was measured at t = 0 months and t = 6 months using a BRAVO wireless pH capsule </plain></SENT>
<SENT sid="8" pm="."><plain>Bile was sampled at the beginning of the UDCA treatment and 6 months later (t = 6 month and t = 12 month) </plain></SENT>
<SENT sid="9" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> biopsies were reviewed for the extent of <z:mpath ids='MPATH_160'>metaplasia</z:mpath>, <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, and <z:hpo ids='HP_0011009'>acute</z:hpo> and <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mp ids='MP_0001845'>inflammation</z:mp> </plain></SENT>
<SENT sid="10" pm="."><plain>In addition, proliferation (Ki67), differentiation (villin, cytokeratins 7 and 20) and <z:mp ids='MP_0001845'>inflammation</z:mp> (COX-2) were investigated by immunohistochemistry (IHC) </plain></SENT>
<SENT sid="11" pm="."><plain>Nine patients (mean age 60 years, median BE length 7 cm) were included, of whom six had no <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and three had low-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> </plain></SENT>
<SENT sid="12" pm="."><plain>pH measurements revealed a <z:mpath ids='MPATH_458'>normal</z:mpath> acid exposure in most patients at t = 0 and t = 6 months </plain></SENT>
<SENT sid="13" pm="."><plain>In addition, bile composition analysis demonstrated the efficacy of UDCA </plain></SENT>
<SENT sid="14" pm="."><plain>Combining the results of both phases of the study, no significant changes were seen in any of the histological or IHC parameters </plain></SENT>
<SENT sid="15" pm="."><plain>Differentiation and proliferation parameters showed no significant changes </plain></SENT>
<SENT sid="16" pm="."><plain>In this study, in BE patients who were clinically asymptomatic on <z:chebi fb="4" ids="53266">PPI</z:chebi>, increasing the <z:chebi fb="4" ids="53266">PPI</z:chebi> dose to the maximum for 6 months followed by the addition of UDCA for 6 months did not result in significant histological or IHC changes in their BE </plain></SENT>
</text></document>